Available Hydroxyurea Products

Hydroxyurea Info

Clinical Overview of Hydroxyurea

Hydroxyurea belongs to the class of antimetabolite agents that interfere with cellular replication. It is the active ingredient in several oral products marketed under the name Hydroxyurea in Singapore. The compound is primarily employed to modulate blood cell production and to reduce the frequency of painful episodes in certain chronic conditions. Its pharmacological profile makes it useful in both oncology and hematology settings, where controlling abnormal cell growth is a therapeutic goal.

Formulations and Products Available Locally

In Singapore, Hydroxyurea is supplied mainly as immediate-release tablets in strengths such as 500 mg. Both generic versions and brand-named tablets can be found in community pharmacies and hospital dispensaries. The tablets are designed for oral ingestion, and the medication is listed under the national drug registry, ensuring consistent quality across manufacturers. While the core active compound remains the same, excipients may differ slightly between products.

Therapeutic Uses Served by This Substance

• Sickle cell disease: The medication helps increase fetal hemoglobin levels, which can lessen the occurrence of vaso-occlusive crises.
• Chronic myelogenous leukemia (CML): It slows the proliferation of malignant white blood cells, contributing to disease control.
• Polycythemia vera: By curbing excess red blood cell production, it assists in maintaining a safer blood thickness.
• Essential thrombocythemia: The drug can reduce elevated platelet counts, decreasing the risk of clot-related events.

These applications reflect the situations where clinicians have observed a benefit from the pharmacologic action of Hydroxyurea. Patients who experience recurring pain episodes, elevated blood cell counts, or specific cancer diagnoses may be offered this option as part of a broader treatment plan.

How the Substance Works in the Body

Hydroxyurea interferes with the synthesis of DNA by limiting the availability of a key building block needed for cell division. This slowdown predominantly affects rapidly dividing cells, such as abnormal blood cells or cancerous cells, thereby reducing their numbers. In sickle cell disease, the same mechanism triggers an increase in fetal hemoglobin, which improves red-cell flexibility and reduces blockage in small vessels. The result is a gradual moderation of disease-related symptoms without completely halting normal cell function.

Safety Profile

Common Reactions

• Mild nausea or loss of appetite
• Low-grade fever for a short period after starting therapy
• Transient skin discoloration or dryness

Serious Reactions

• Sudden severe anemia or unusually low blood counts
• Acute liver discomfort accompanied by jaundice
• Unexpected bruising or bleeding that does not stop quickly

Contraindications

• Individuals with known hypersensitivity to Hydroxyurea
• Pregnant or breastfeeding persons, as safety data are limited
• Patients with severe liver impairment should avoid use unless specifically directed

Interaction Awareness

• Alcohol consumption may enhance liver stress, so moderate intake is advisable.
• Concurrent use of other myelosuppressive agents can amplify blood-cell suppression.
• Certain antiretroviral drugs may alter the metabolism of this compound.

For comprehensive interaction details, refer to the specific medication’s information sheet.

Practical Considerations for Patients

Tablets should be stored in a cool, dry place away from direct sunlight, and kept out of reach of children. Treatment duration varies; some regimens are short-term for cancer control, while others are chronic for sickle cell disease management. The exact length of therapy and dosage adjustments are tailored to each individual medication, so reviewing the product label is essential. For precise usage instructions, dosing schedules, and administration techniques, consult the clinical information accompanying the specific Hydroxyurea medication.

Key Terminology

• Antimetabolite: A class of drugs that hinder the synthesis of nucleic acids, affecting cell growth.
• Fetal hemoglobin: A form of hemoglobin present at birth that can improve red-cell flexibility when re-induced in adulthood.
• Myelosuppression: Reduction in the bone-marrow’s ability to produce blood cells, a common effect of certain therapies.
• Vaso-occlusive crisis: Painful blockage of blood flow, frequently seen in sickle cell disease.

Important Usage Disclosure

This article offers an educational overview of Hydroxyurea as an active substance and does not constitute medical advice. Individual medicines containing this compound may differ in formulation, strength, and recommended directions. The information provided carries no liability for clinical decision-making. Patients should review the labeling of their specific product and, when needed, consult a healthcare professional for personalized guidance.